177 related articles for article (PubMed ID: 35787784)
21. Alpelisib for the treatment of PIK3CA-related head and neck lymphatic malformations and overgrowth.
Wenger TL; Ganti S; Bull C; Lutsky E; Bennett JT; Zenner K; Jensen DM; Dmyterko V; Mercan E; Shivaram GM; Friedman SD; Bindschadler M; Drusin M; Perkins JN; Kong A; Bly RA; Dahl JP; Bonilla-Velez J; Perkins JA
Genet Med; 2022 Nov; 24(11):2318-2328. PubMed ID: 36066547
[TBL] [Abstract][Full Text] [Related]
22. Consistency and reproducibility of next-generation sequencing and other multigene mutational assays: A worldwide ring trial study on quantitative cytological molecular reference specimens.
Malapelle U; Mayo-de-Las-Casas C; Molina-Vila MA; Rosell R; Savic S; Bihl M; Bubendorf L; Salto-Tellez M; de Biase D; Tallini G; Hwang DH; Sholl LM; Luthra R; Weynand B; Vander Borght S; Missiaglia E; Bongiovanni M; Stieber D; Vielh P; Schmitt F; Rappa A; Barberis M; Pepe F; Pisapia P; Serra N; Vigliar E; Bellevicine C; Fassan M; Rugge M; de Andrea CE; Lozano MD; Basolo F; Fontanini G; Nikiforov YE; Kamel-Reid S; da Cunha Santos G; Nikiforova MN; Roy-Chowdhuri S; Troncone G;
Cancer Cytopathol; 2017 Aug; 125(8):615-626. PubMed ID: 28475299
[TBL] [Abstract][Full Text] [Related]
23. Major challenges related to tumor biological characteristics in accurate mutation detection of colorectal cancer by next-generation sequencing.
Li W; Qiu T; Guo L; Ying J
Cancer Lett; 2017 Dec; 410():92-99. PubMed ID: 28942013
[TBL] [Abstract][Full Text] [Related]
24. Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial.
Normanno N; Rachiglio AM; Lambiase M; Martinelli E; Fenizia F; Esposito C; Roma C; Troiani T; Rizzi D; Tatangelo F; Botti G; Maiello E; Colucci G; Ciardiello F;
Ann Oncol; 2015 Aug; 26(8):1710-4. PubMed ID: 25851630
[TBL] [Abstract][Full Text] [Related]
25. Bosutinib Inhibits EGFR Activation in Head and Neck Cancer.
Segrelles C; Contreras D; Navarro EM; Gutiérrez-Muñoz C; García-Escudero R; Paramio JM; Lorz C
Int J Mol Sci; 2018 Jun; 19(7):. PubMed ID: 29933569
[TBL] [Abstract][Full Text] [Related]
26. DW09849, a selective phosphatidylinositol 3-kinase (PI3K) inhibitor, prevents PI3K signaling and preferentially inhibits proliferation of cells containing the oncogenic mutation p110α (H1047R).
Liu JL; Gao GR; Zhang X; Cao SF; Guo CL; Wang X; Tong LJ; Ding J; Duan WH; Meng LH
J Pharmacol Exp Ther; 2014 Mar; 348(3):432-41. PubMed ID: 24361696
[TBL] [Abstract][Full Text] [Related]
27. Blockade of VEGF-C signaling inhibits lymphatic malformations driven by oncogenic PIK3CA mutation.
Martinez-Corral I; Zhang Y; Petkova M; Ortsäter H; Sjöberg S; Castillo SD; Brouillard P; Libbrecht L; Saur D; Graupera M; Alitalo K; Boon L; Vikkula M; Mäkinen T
Nat Commun; 2020 Jun; 11(1):2869. PubMed ID: 32513927
[TBL] [Abstract][Full Text] [Related]
28. Vascular Anomalies: From a Clinicohistologic to a Genetic Framework.
Greene AK; Goss JA
Plast Reconstr Surg; 2018 May; 141(5):709e-717e. PubMed ID: 29697621
[TBL] [Abstract][Full Text] [Related]
29. Next generation MUT-MAP, a high-sensitivity high-throughput microfluidics chip-based mutation analysis panel.
Schleifman EB; Tam R; Patel R; Tsan A; Sumiyoshi T; Fu L; Desai R; Schoenbrunner N; Myers TW; Bauer K; Smith E; Raja R
PLoS One; 2014; 9(3):e90761. PubMed ID: 24658394
[TBL] [Abstract][Full Text] [Related]
30. The YAP signaling pathway promotes the progression of lymphatic malformations through the activation of lymphatic endothelial cells.
Zhong W; Jiang H; Zou Y; Ren J; Li Z; He K; Zhao J; Zhou X; Mou D; Cai Y
Pediatr Res; 2021 Jan; 89(1):110-117. PubMed ID: 32279070
[TBL] [Abstract][Full Text] [Related]
31. The gene mutational discrepancies between primary and paired metastatic colorectal carcinoma detected by next-generation sequencing.
Zou SM; Li WH; Wang WM; Li WB; Shi SS; Ying JM; Lyu N
J Cancer Res Clin Oncol; 2018 Nov; 144(11):2149-2159. PubMed ID: 30171333
[TBL] [Abstract][Full Text] [Related]
32. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
Genet Med; 2013 Jul; 15(7):517-27. PubMed ID: 23429431
[TBL] [Abstract][Full Text] [Related]
33. Decrease in phosphorylated ERK indicates the therapeutic efficacy of a clinical PI3Kα-selective inhibitor CYH33 in breast cancer.
Liu XL; Xu YC; Wang YX; Chen Y; Wang BB; Wang Y; Chen YH; Tan C; Hu LD; Ma QY; Zhang YC; Sun YM; Gao YL; Yang CH; Ding J; Meng LH
Cancer Lett; 2018 Oct; 433():273-282. PubMed ID: 30003928
[TBL] [Abstract][Full Text] [Related]
34. Dermatologic adverse events related to the PI3Kα inhibitor alpelisib (BYL719) in patients with breast cancer.
Wang DG; Barrios DM; Blinder VS; Bromberg JF; Drullinsky PR; Funt SA; Jhaveri KL; Lake DE; Lyons T; Modi S; Razavi P; Sidel M; Traina TA; Vahdat LT; Lacouture ME
Breast Cancer Res Treat; 2020 Aug; 183(1):227-237. PubMed ID: 32613539
[TBL] [Abstract][Full Text] [Related]
35. Clinical validation of coexisting driver mutations in colorectal cancers.
Zheng G; Tseng LH; Haley L; Ibrahim J; Bynum J; Xian R; Gocke CD; Eshleman JR; Lin MT
Hum Pathol; 2019 Apr; 86():12-20. PubMed ID: 30481508
[TBL] [Abstract][Full Text] [Related]
36. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1.
André F; Ciruelos EM; Juric D; Loibl S; Campone M; Mayer IA; Rubovszky G; Yamashita T; Kaufman B; Lu YS; Inoue K; Pápai Z; Takahashi M; Ghaznawi F; Mills D; Kaper M; Miller M; Conte PF; Iwata H; Rugo HS
Ann Oncol; 2021 Feb; 32(2):208-217. PubMed ID: 33246021
[TBL] [Abstract][Full Text] [Related]
37. Construction of a reference material panel for detecting
Xu J; Qu S; Sun N; Zhang W; Zhang J; Song Q; Lin M; Gao W; Zheng Q; Han M; Na C; Xu R; Chang X; Yang X; Huang J
J Clin Pathol; 2021 May; 74(5):314-320. PubMed ID: 32817175
[TBL] [Abstract][Full Text] [Related]
38. PIK3CA mutations in advanced cancers: characteristics and outcomes.
Janku F; Wheler JJ; Naing A; Stepanek VM; Falchook GS; Fu S; Garrido-Laguna I; Tsimberidou AM; Piha-Paul SA; Moulder SL; Lee JJ; Luthra R; Hong DS; Kurzrock R
Oncotarget; 2012 Dec; 3(12):1566-75. PubMed ID: 23248156
[TBL] [Abstract][Full Text] [Related]
39. Pharmacological mTOR targeting enhances the antineoplastic effects of selective PI3Kα inhibition in medulloblastoma.
Eckerdt F; Clymer J; Bell JB; Beauchamp EM; Blyth GT; Goldman S; Platanias LC
Sci Rep; 2019 Sep; 9(1):12822. PubMed ID: 31492956
[TBL] [Abstract][Full Text] [Related]
40. Somatic Activating PIK3CA Mutations Cause Venous Malformation.
Limaye N; Kangas J; Mendola A; Godfraind C; Schlögel MJ; Helaers R; Eklund L; Boon LM; Vikkula M
Am J Hum Genet; 2015 Dec; 97(6):914-21. PubMed ID: 26637981
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]